WG EWAIT / EGUARD Brussels, WE 10th March
Meeting minutes
Attendants: 21
6
7
8
9
Name
Antonio Aritgas
Mercedes Palomar (J.
Rello)
Jan J de Waele
Pawel Sobczynski,
Ignacio MartinLoeches
Sascha Tafelski
Lutz Kaufner
Claudia Spies
Hynek Fiala
10
11
12
13
14
15
16
17
18
19
20
21
Laura Zavatti
Massimo Giradis
Despoina Koulenti
Finn Radke
Willehad Boemke
Rui Moreno
Andy Rhodes
Michael Hiesmayr
Ioana Grigoras
Charles Sprung
Håkan Hanberger
Dalia Adukauskiene
1
2
3
4
5
Country
Spain
Spain
E-mail
aartigas@cspt.es
mpalomar@vhebron.net
Belgium
Poland
Spain
jan.dewaele@ugent.be
psobczynski@me.com
drmartinloeches@gmail.com
Germany
Germany
Germany
Czech
Republic
Italy
Italy
Greece
Germany
Germany
Portugal
U.K.
Austria
Romania
Israel
Sweden
Lithuania
Sascha.tafelski@charite.de
Lutz.kaufner@charite.de
Claudia.spies@charite.de
Hynek.Fiala@fnol.cz
doczav@hotmail.com
girardis.massimo@unimore.it
deskogr@yahoo.gr
finn.radke@charite.de
Willehad.boemke@charite.de
moreno.rui@gmail.com
andyr@sgul.ac.uk
michael.hiesmayr@meduniwien.ac.at
grigorasioana@yahoo.com
sprung@cc.huji.ac.il
hakan.hanberger@liu.se
daliaadu@gmail.com
1. Presentation of the current draft of the FP7 Cooperation Work Programme: Health2011, CONFIDENTIAL DRAFT 1, Version: 15 Jan. 2010 Work Programme 2011, First
draft COOPERATION, THEME 1: Health (L. Kaufner)

Two main themes in the health program, which might be interesting for EGUARD,
will be closed in 2011:
o 1.2 DETECTION, DIAGNOSIS AND MONITORING
Closed in 2011
o 1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES
Closed in 2011


The topics will be open next year, therefore AMR will be closed in the call
next year.
The upcoming call focused on antimicrobial resistance and continuing to
adress emerging epidemics.
In antimicrobial resistance the focus will be on understanding of the evolution and
the transfer of antibiotic resistance as well as antimicrobial drug resistance
in Gram negative infections and developing multi-analyte diagnostics.
For EGUARD area 2.3. and the themes on AMR- specially development on
multianalytic tests might be interesting:
HEALTH.2011.2.3.1-4 Development of multi-analyte diagnostic tests.
Development of multi-analyte diagnostic tests. FP7-HEALTH-2011-two-stage.
Research should aim to develop novel diagnostic tools. Managing the problem of bacterial
resistance relies on a fast identification of resistant pathogens in a clinical setting. The
vast
numbers of pathogenic bacteria that can contain a variety of resistance mechanisms
stress the
need for multi-analyte diagnostic tests that are fast and reliable. Tests should aim to
distinguish bacteria from viruses, should detect markers for severity of infection and
identify
resistance/susceptibility patterns. The availability of robust diagnostic tests is required to
allow for an evidence-based system of antibiotic resistance management. The
development of
such diagnostic tools and their introduction in clinical settings should be aimed for, with
the
ultimate goal to tailor antibiotic prescription to the individual patient. All consortia should
aim at having 30-50 % of the requested EC contribution budget going to SMEs
(subcontracting is discouraged). Note: Limits on the EC financial contribution apply.
These
are implemented strictly as formal eligibility criteria.
Funding scheme: Collaborative Project (small or medium-scale SME focused research
project).
EC contribution per project: max. EUR 3 000 000.
One or more proposals can be selected.
Expected impact: The availability of multi-analyte diagnostic tests will allow for antibiotic
prescription that takes both the type of (resistant) infection of the patient, and the
presence of
resistant pathogens in the clinical setting into account.
Justification: There is a clear need for novel diagnostic tools, which was also highlighted
at the major conference on "Innovative Incentives for Effective Antibacterials" organised
by the Swedish Presidency in September 2009 as well as in two expert workshops on
research priorities organized at ECDC and at DG RTD in November 2009. Such tools are
required for high quality medical decision-making and the management of antibiotic
resistance in health care settings.

Research priorities of the commission concerning multianalytic diagnostics tests
related to the call Justification:












noval diagnostic test
tailored antibiotic prescription
high qualitiy medical decision-making
management of antibiotic resistance
clear coupling to patient needs
conserve existing antibiotics
effective treatment available
minimizing costs
rapid point of care identification + therapy
right choice of effective drugs
reduction of antibiotic use
limited and narrower antibiotic use
So EGUARD seems to be in line with the ECDC research priorities, but the
absence of the “therapy part” (combined with novel diagnostic tests) in the call
text and justification requires a call modification which was submitted by different
partners via the NCP.
Call modification:
Development of multi-analyte diagnostic tests and decision support tools for anti-infective
treatment. FP7-HEALTH-2011-two-stage.
Research should aim to develop novel diagnostic tools linked with a rapid point-of-care decision
support in anti-infective treatment. Managing the problem of bacterial resistance relies on a fast
identification of resistant pathogens in a clinical setting. The vast numbers of pathogenic bacteria
that can contain a variety of resistance mechanisms stress the need for combined multi-analyte
diagnostic tests and therapeutic decision support tools that are fast and reliable. Tests should aim
to distinguish bacteria from viruses, should detect markers for severity of infection and identify
resistance/susceptibility patterns. The availability of robust diagnostic tests and therapeutic tools is
required to allow for an evidence-based system of antibiotic resistance management and a fast and
appropriate use of antibiotics. The development of such diagnostic tools and their introduction in
clinical settings should be aimed for, with the ultimate goal to tailor antibiotic prescription to the
individual patient. All consortia should aim at having 30-50 % of the requested EC contribution
budget going to SMEs.
Opportunities for the EGUARD project resulting from the current FP7-HEALTH2011 :
1. Waiting for FP7-Health-2012, open calls for DETECTION, DIAGNOSIS
AND MONITORING as well as SUITABILITY, SAFETY, EFFICACY OF
THERAPIES (AMR closed in 2012)
2. „Call modification“ via National Contact Points: Implementation of CDSS into
the call text, EGUARD retains the coordination of project
3. EGUARD as single working package in a SME tailored project on AMR
diagnostics
Comments:
 Charles Sprung: If meeting goals this year, take this chance: Other program
was 2 times rejected – getting the information what reviewers like.
 EGUARD analysis – partner ideas?
a. perhaps via Charles Sprung, will contact a company on a
confidential basis
b. Time enough for finding SME? C. Spies: There will be enough time
for SME partnership on diagnostics provide that the “therapy
modul” will be include into the call (Call modification)
c. Basic science of microbiologists- should be an idea to ask this
specialty
d. SME company are under development, but not done by SMEs but
global players
e. MDR in abdomen is different to MDR of pneumonia, it will be
difficult to cover of
f. PCT? (“old”); decision tool to test who gets the antibiotics;
Pentroxin3; small company of US
g. IDEA: Stratification system to find nosocomial
h. IDEA: getting Candida / Mycoses infections: Some new ideas are
out there
i. IDEA: Empirical Antifungal Therapy guidance beyond the
immuno- compromised infection

Final meeting minutes:
o Dependent on the final call text and implementation of
therapy and CDSS into the call text (call modification) the
EGAURD WG should apply for FP 7 funding, WG EGUARD
retains the coordination of project
o If there is no change in the call, the WG EGUARD should
reconsider the application for FP 7 funding this year. Therefore
alternative European funding possibilities should be proved by the
WG (e.g. funding of the EU DG SANCO). Additional the WG
concluded to apply for the call 2012 and the open topics on
DETECTION, DIAGNOSIS AND MONITORING as well as
SUITABILITY, SAFETY, EFFICACY OF THERAPIES (AMR
closed in 2012).
o Accompanying measures: Scheduling EGUARD Barcelona
meeting; Topic submission via NCP for the call 2012;
Invitation and involvement of the responsible science officer;
further implementation of the EGUARD programme into
national or international multicenter studies in between the
WG (Cooperation Artigas/Spain and Giradis/Italy)
2. Presentation of different design drafts of the EGUARD logo (L. Kaufner).
A vast majority of the meeting participants and EGUARD members voted for the
following logo: